Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.22 +0.13 (+0.93%)

Streaming Delayed Price Updated: 3:03 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

18 19 Next >

Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

April 04, 2023

B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell...

Via Benzinga

Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners

April 03, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

March 30, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Zoetis Stock Shows Rising Relative Strength Upgrades ↗

February 17, 2023

Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Via Investor's Business Daily

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

March 30, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

March 30, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗

March 27, 2023

Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.

Via Investor's Business Daily

BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.

March 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million ↗

March 25, 2023

HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product...

Via Talk Markets

Price Growth & Yield: For That Magical Combo, Leave the U.S.

March 21, 2023

Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.

Via MarketBeat

Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says ↗

March 20, 2023

Via Benzinga

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis

March 18, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session

March 17, 2023

Via Investor Brand Network

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗

March 16, 2023

Via Benzinga

Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies ↗

March 15, 2023

Via Benzinga

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

March 14, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Should You Give Up on Novavax? ↗

March 03, 2023

After a spectacular 2020 performance, Novavax's shares have plummeted.

Via The Motley Fool

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing ↗

March 02, 2023

The FDA made a bold move in the CRISPR gene-editing realm.

Via Investor's Business Daily

2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now ↗

February 28, 2023

These two high-yield dividend stocks are trading at bargain-basement prices.

Via The Motley Fool

Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients ↗

February 21, 2023

Via Benzinga

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

February 18, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Is This the Telltale Sign to Sell Novavax Stock? ↗

February 14, 2023

You won't find Novavax's latest bad news trumpeted in a press release.

Via The Motley Fool

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary

February 08, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

NeurAxis: Should You Buy This IPO? ↗

February 08, 2023

As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.

Via Talk Markets

NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution ↗

February 06, 2023

As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.

Via Talk Markets

U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

February 03, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged ↗

February 02, 2023

Via Benzinga

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

February 02, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 Sorry Dividend Stocks to Sell in February Before It’s Too Late ↗

January 30, 2023

These dividend stocks to sell have weak underlying fundamentals, offering little upside potential ahead for investors.

Via InvestorPlace

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.